Nebenwirkungen · Taxotere
TAXOTERE 20 mg/1 mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 104
HOS-084793 · Präparat HOS-083047
General disorders and administration site conditions The median cumulative dose to treatment discontinuation was more than 1 000 mg/m2 and the median time to fluid retention reversibility was 16.4 weeks (range 0 to 42 weeks). The onset of moderate and severe retention is delayed (median cumulative dose: 818.9 mg/m2) in patients with premedication compared with patients without premedication (median cumulative dose: 489.7 mg/m2); however, it has been reported in some patients during the early courses of therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T16:45:00Z · SHA-256 518a48b73ebbaf067647805c9944cdf9fe7e9826b63e3719c8c44fa589fb5cce · Passage 72c9be6b6c3768c6f108f7abca2d8e1be7a28717b3bde0f869f40a90878621b6 · Zeichen 9815–10331 im Abschnitt